Skip to Main Content

Paper Details

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
medRxiv
3
2023
B cell, BNT162b2, BNT162b2 mRNA, HIV, SARS-CoV-2, T-, T-cell, anti-SARS-CoV-2 binding antibody, participants
Author NameAffiliation
Alessandro SetteCenter for Vaccine Innovation, La Jolla Institute for Immunology
Alessandro SetteUniversity of California, San Diego (university of california san diego)
Alessandro SetteCenter for Vaccine Innovation, La Jolla Institute for Immunology
Alessandro SetteUniversity of California, San Diego (university of california san diego)
  • 1 - 4

Datasets

Release 1.2